simply hugeeee!!!, page-46

Motor I don't think you have to be Einstien to realize news is needed to move forward.
I also see this part of the release as positive

Given Professor Gleave?s successful studies specifically related to the prostate cancer application of
ATL1101, ANP will continue to seek a development partner primarily for this indication. ANP is in
discussions with other parties interested in the development of ATL1101 for prostate cancer2%3B%7D

- ATL1101 for prostate cancer. This follows successful
animal studies where ATL1101 was shown to suppress human prostate tumour growth. These studies were
conducted as part of a collaborative research program with leading prostate cancer researcher, Professor
Martin Gleave at the Vancouver Prostate Cancer Centre.117


The other company what discontinued there Research was eveluating ATL1101 in a different (non prostate) tumour system and
determined not to proceed with further experimental work on ATL1101.
This specific outcome does not affect ANP?s partnering plans for the further development of ATL1101 as083


While I agree rob quality of analysis is dreadful. I do find disturbing that it seems a few including you have seemed to have missed the crux of the announcement.

1 It is a prostate cancer application
2 It worked successfully on and suppress human prostate tumour growth
3 That it doesn't work on some other tumours is not a negative but it show how the prostate tumour is compeletly different and cannot be treated like other tumours, Hence the specific focus prostate cancer tumours.

Motor to demand quality of one's peers and then to post what have is how would one say, "the pot calling the kettle black" By all means have your say but to demand quality one must also deliver it to.